Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α

Francesco M. Marincola, Stephen Ettinghausen, Peter A Cohen, L. Bryan Cheshire, Nicholas P. Restifo, James J. Mule, Steven A. Rosenberg

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The growth of a poorly immunogenic methylcholanthrene (MCA)-induced murine (m) sarcoma genetically engineered to secrete human (h) TNF-α (MCA-102- hTNF) was studied. MCA-102-hTNF tumor cells were implanted in animals bearing three- or 7-day pulmonary metastases established with the parental line MCA- 102-WT (wild type). This model approximates the clinical situation in which patients with metastatic cancer would be vaccinated with autologous tumor genetically modified to stimulate the host immune response. Reduction in the number of pulmonary metastases was occasionally seen but was not consistently reproducible. Other cytokine-producing tumors had either no effect on distant pulmonary metastases (mIL-4, IFN-γ) or a mild, inconclusive effect similar to hTNF-α (mTNF-α). Significant growth inhibition of MCA-102-hTNF was noted in animals bearing pulmonary metastases. This inhibition was: 1) tumor specific (regression occurred only in animals bearing pulmonary metastases from the same parental line), 2) TNF specific (it was inhibited by in vivo administration of anti hTNF mAbs), 3) dependent on cellular immunity (immune- depletion with anti-CD4 or CD8 mAbs permitted growth). Tumor-infiltrating lymphocytes (TIL) could not be grown from MCA-102-WT or MCA-102-hTNF tumors nor from MCA-102-WT subcutaneous implants in mice bearing MCA-102-WT pulmonary metastases. However, TIL could be grown from hTNF-secreting tumors implanted in mice bearing MCA-102-WT metastases. These TIL were therapeutic against established lung metastases from the parental tumor in adoptive immunotherapy models. These studies suggest a strategy for using gene modified tumors for the therapy of established cancer.

Original languageEnglish (US)
Pages (from-to)3501-3513
Number of pages13
JournalJournal of Immunology
Volume152
Issue number7
StatePublished - Apr 1 1994
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Methylcholanthrene
Neoplasm Metastasis
Lung
Neoplasms
Therapeutics
Growth
Adoptive Immunotherapy
Cellular Immunity
Sarcoma
Cytokines

ASJC Scopus subject areas

  • Immunology

Cite this

Marincola, F. M., Ettinghausen, S., Cohen, P. A., Cheshire, L. B., Restifo, N. P., Mule, J. J., & Rosenberg, S. A. (1994). Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α. Journal of Immunology, 152(7), 3501-3513.

Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α. / Marincola, Francesco M.; Ettinghausen, Stephen; Cohen, Peter A; Cheshire, L. Bryan; Restifo, Nicholas P.; Mule, James J.; Rosenberg, Steven A.

In: Journal of Immunology, Vol. 152, No. 7, 01.04.1994, p. 3501-3513.

Research output: Contribution to journalArticle

Marincola, FM, Ettinghausen, S, Cohen, PA, Cheshire, LB, Restifo, NP, Mule, JJ & Rosenberg, SA 1994, 'Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α', Journal of Immunology, vol. 152, no. 7, pp. 3501-3513.
Marincola, Francesco M. ; Ettinghausen, Stephen ; Cohen, Peter A ; Cheshire, L. Bryan ; Restifo, Nicholas P. ; Mule, James J. ; Rosenberg, Steven A. / Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α. In: Journal of Immunology. 1994 ; Vol. 152, No. 7. pp. 3501-3513.
@article{4fdc4706ca0d4f609f6a17be14669f5b,
title = "Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α",
abstract = "The growth of a poorly immunogenic methylcholanthrene (MCA)-induced murine (m) sarcoma genetically engineered to secrete human (h) TNF-α (MCA-102- hTNF) was studied. MCA-102-hTNF tumor cells were implanted in animals bearing three- or 7-day pulmonary metastases established with the parental line MCA- 102-WT (wild type). This model approximates the clinical situation in which patients with metastatic cancer would be vaccinated with autologous tumor genetically modified to stimulate the host immune response. Reduction in the number of pulmonary metastases was occasionally seen but was not consistently reproducible. Other cytokine-producing tumors had either no effect on distant pulmonary metastases (mIL-4, IFN-γ) or a mild, inconclusive effect similar to hTNF-α (mTNF-α). Significant growth inhibition of MCA-102-hTNF was noted in animals bearing pulmonary metastases. This inhibition was: 1) tumor specific (regression occurred only in animals bearing pulmonary metastases from the same parental line), 2) TNF specific (it was inhibited by in vivo administration of anti hTNF mAbs), 3) dependent on cellular immunity (immune- depletion with anti-CD4 or CD8 mAbs permitted growth). Tumor-infiltrating lymphocytes (TIL) could not be grown from MCA-102-WT or MCA-102-hTNF tumors nor from MCA-102-WT subcutaneous implants in mice bearing MCA-102-WT pulmonary metastases. However, TIL could be grown from hTNF-secreting tumors implanted in mice bearing MCA-102-WT metastases. These TIL were therapeutic against established lung metastases from the parental tumor in adoptive immunotherapy models. These studies suggest a strategy for using gene modified tumors for the therapy of established cancer.",
author = "Marincola, {Francesco M.} and Stephen Ettinghausen and Cohen, {Peter A} and Cheshire, {L. Bryan} and Restifo, {Nicholas P.} and Mule, {James J.} and Rosenberg, {Steven A.}",
year = "1994",
month = "4",
day = "1",
language = "English (US)",
volume = "152",
pages = "3501--3513",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α

AU - Marincola, Francesco M.

AU - Ettinghausen, Stephen

AU - Cohen, Peter A

AU - Cheshire, L. Bryan

AU - Restifo, Nicholas P.

AU - Mule, James J.

AU - Rosenberg, Steven A.

PY - 1994/4/1

Y1 - 1994/4/1

N2 - The growth of a poorly immunogenic methylcholanthrene (MCA)-induced murine (m) sarcoma genetically engineered to secrete human (h) TNF-α (MCA-102- hTNF) was studied. MCA-102-hTNF tumor cells were implanted in animals bearing three- or 7-day pulmonary metastases established with the parental line MCA- 102-WT (wild type). This model approximates the clinical situation in which patients with metastatic cancer would be vaccinated with autologous tumor genetically modified to stimulate the host immune response. Reduction in the number of pulmonary metastases was occasionally seen but was not consistently reproducible. Other cytokine-producing tumors had either no effect on distant pulmonary metastases (mIL-4, IFN-γ) or a mild, inconclusive effect similar to hTNF-α (mTNF-α). Significant growth inhibition of MCA-102-hTNF was noted in animals bearing pulmonary metastases. This inhibition was: 1) tumor specific (regression occurred only in animals bearing pulmonary metastases from the same parental line), 2) TNF specific (it was inhibited by in vivo administration of anti hTNF mAbs), 3) dependent on cellular immunity (immune- depletion with anti-CD4 or CD8 mAbs permitted growth). Tumor-infiltrating lymphocytes (TIL) could not be grown from MCA-102-WT or MCA-102-hTNF tumors nor from MCA-102-WT subcutaneous implants in mice bearing MCA-102-WT pulmonary metastases. However, TIL could be grown from hTNF-secreting tumors implanted in mice bearing MCA-102-WT metastases. These TIL were therapeutic against established lung metastases from the parental tumor in adoptive immunotherapy models. These studies suggest a strategy for using gene modified tumors for the therapy of established cancer.

AB - The growth of a poorly immunogenic methylcholanthrene (MCA)-induced murine (m) sarcoma genetically engineered to secrete human (h) TNF-α (MCA-102- hTNF) was studied. MCA-102-hTNF tumor cells were implanted in animals bearing three- or 7-day pulmonary metastases established with the parental line MCA- 102-WT (wild type). This model approximates the clinical situation in which patients with metastatic cancer would be vaccinated with autologous tumor genetically modified to stimulate the host immune response. Reduction in the number of pulmonary metastases was occasionally seen but was not consistently reproducible. Other cytokine-producing tumors had either no effect on distant pulmonary metastases (mIL-4, IFN-γ) or a mild, inconclusive effect similar to hTNF-α (mTNF-α). Significant growth inhibition of MCA-102-hTNF was noted in animals bearing pulmonary metastases. This inhibition was: 1) tumor specific (regression occurred only in animals bearing pulmonary metastases from the same parental line), 2) TNF specific (it was inhibited by in vivo administration of anti hTNF mAbs), 3) dependent on cellular immunity (immune- depletion with anti-CD4 or CD8 mAbs permitted growth). Tumor-infiltrating lymphocytes (TIL) could not be grown from MCA-102-WT or MCA-102-hTNF tumors nor from MCA-102-WT subcutaneous implants in mice bearing MCA-102-WT pulmonary metastases. However, TIL could be grown from hTNF-secreting tumors implanted in mice bearing MCA-102-WT metastases. These TIL were therapeutic against established lung metastases from the parental tumor in adoptive immunotherapy models. These studies suggest a strategy for using gene modified tumors for the therapy of established cancer.

UR - http://www.scopus.com/inward/record.url?scp=84901964983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901964983&partnerID=8YFLogxK

M3 - Article

C2 - 8144931

AN - SCOPUS:84901964983

VL - 152

SP - 3501

EP - 3513

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -